In consistent to ameliorated lipid accumulation and lipotoxicity, enhanced FAO via LCA promoted insulin-stimulated glucose uptake, thus restored random blood glucose in obesity (Figure 5)
In VISTA (n=310), adults with obesity or overweight and at least one comorbidity receiving elecoglipron (75mg) achieved a clinically meaningful and statistically significant average reduction in body weight of 10.5% at 26 weeks compared to 0.6% with placebo, a dual primary endpoint
Confounding by obesity (which itself increases autoimmune risk)
For example, triglycerides, total cholesterol, and fasting glucose show high correlation between clinical lab vendors, while LDL particle number is less correlated
Mastrandrea L, Yu J, Behrens T et al (2009) Etanercept treatment in children with new-onset type 1 diabetes